How it works:
Palbociclib inhibits cyclin-dependent kinases CDK4 and CDK6, which are essential for cell cycle progression from the G1 to S phase. By blocking this pathway, the drug halts cancer cell proliferation. Palbociclib is most effective when combined with endocrine therapy in patients with ER-positive and HER2-negative tumours.
Recommended For:
Postmenopausal women with HR+/HER2- advanced or metastatic breast cancer
In combination with an aromatase inhibitor such as letrozole
In combination with fulvestrant after disease progression
Under oncologist supervision only
Patients requiring oral targeted cancer therapy
HR-positive, HER2-negative locally advanced or metastatic breast cancer
First-line treatment with aromatase inhibitors
Subsequent therapy with fulvestrant after progression
PALNAT 125mg is taken once daily for 21 consecutive days, followed by a 7-day break, making a 28-day cycle. The capsules should be taken at the same time daily, with or without food. Dose modifications may be required depending on patient tolerance and blood test results.
Contraindications:
Hypersensitivity to palbociclib or any component of the formulation
Pregnancy and breastfeeding
Severe hepatic impairment
Paediatric use is not recommended
Side Effects:
Neutropenia, leukopenia
Anaemia
Upper respiratory tract infections
Fatigue
Nausea, diarrhoea
Hair thinning (alopecia)
Elevated liver enzymes
Rare: Interstitial lung disease
